Search Results 281-290 of 12298 for Multiple myeloma red flag
Sakemura is working to advance immunotherapy efficacy in multiple myeloma cancer by uncovering treatment resistance mechanisms and developing a more potent ...
Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...
Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior ...
Clinical Trials · A Study Of JNJ‐68284528 Out‐of‐Specification (OOS) For Commercial Release In Patients With Multiple Myeloma · More about research at Mayo Clinic.
Monoclonal gammopathy of undetermined significance (MGUS). Multiple myeloma, which is a type of blood cancer. Light chain amyloidosis. Their work includes using ...
... multiple myeloma (MM) that are associated with populations at high risk for developing these conditions using an online survey and submission of de ...
A Study To Evaluate The Safety, Tolerance And Anti-tumor Activity Of SAR442257 In Patients With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Non ...
Multiple myeloma is the second-most common blood cancer, and the risk is higher among men, Black Americans and people with a family history of the disease.
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated ...
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.